Results 111 to 120 of about 18,076 (169)
Some of the next articles are maybe not open access.
Review of the acetylcholinesterase inhibitor galanthamine
Expert Opinion on Investigational Drugs, 2000Galanthamine (or galantamine, Reminyl) is a tertiary alkaloid acetylcholinesterase inhibitor (AChEI) which has been approved in several countries for the symptomatic treatment of senile dementia of the Alzheimer's type. Derived from bulbs of the common snowdrop and several Amaryllidaceae plants, (-)-galanthamine (GAL) has long been used in anaesthetics
N R Cutler, J J Sramek
exaly +3 more sources
Radioimmunoassay for the Quantitative Determination of Galanthamine
Planta Medica, 1990A radioimmunoassay for the quantitation of pmol amounts of the therapeutically important Amaryllidaceae alkaloid, galanthamine, has been developed. The antiserum was raised against a conjugate of galanthamine-2-O-hemisuccinate-bovine serum albumin. The measuring range of the assay extends from 0.5 to 100 ng of galanthamine, and as little as 3.5 pmol ...
Alexander Poulev +2 more
exaly +3 more sources
The pharmacology of galanthamine and its analogues
Pharmacology & Therapeutics, 1995Galanthamine is an alkaloid found in the bulbs of snowdrops and several Amaryllidaceae plants. At submicromolar concentrations, it inhibits acetylcholinesterase activity, but it is much less potent against butyrylcholinesterase activity. Galanthamine has been used in anaesthetics to reverse neuromuscular paralysis by tubocurarine-like muscle relaxants,
A L Harvey, Alan L Harvey
exaly +5 more sources
Drugs & Aging, 1996
Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galanthamine is selective for acetylcholinesterase versus butyrylcholinesterase; however, the drug produces greater enzyme inhibition in human erythrocytes than in human brain tissue.
B, Fulton, P, Benfield
+5 more sources
Galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of Alzheimer's disease. Galanthamine is selective for acetylcholinesterase versus butyrylcholinesterase; however, the drug produces greater enzyme inhibition in human erythrocytes than in human brain tissue.
B, Fulton, P, Benfield
+5 more sources
Total Synthesis of (±)-Galanthamine
Organic Letters, 2006[reaction: see text] A practical and efficient total synthesis of (+/-)-galanthamine was achieved from commercially available materials through a novel approach, in which the construction of its core structure and the special allylic alcohol group were based on a successive semipinacol rearrangement/desilyation/cyclization and Saegusa-Ito oxidation ...
Xiang-Dong, Hu +7 more
openaire +2 more sources
Cholinesterase inhibition by galanthamine and lycoramine
Biochemical Pharmacology, 1960Abstract Galanthamine, a recently isolated alkaloid, has been found to inhibit the acetylcholinesterase of muscle and the cholinesterase of plasma and brain. The inhibition of the muscle enzyme by galanthamine is greater than that produced by pyridostigmin, a compound of known usefulness, but less than that of neostigmin.
R L, IRWIN, H J, SMITH
openaire +2 more sources
Galanthamine treatment in Alzheimer’s disease
199118 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results.
P, Dal-Bianco +8 more
openaire +2 more sources
An improved synthesis of galanthamine
Journal of Heterocyclic Chemistry, 1988AbstractModifications in the total synthesis of the Amarylidaceae alkaloid of galanthamine from commercially available isovanillin and tyramine have resulted in a shortened reaction sequence, which is amenable to upscaling and in improved product yield.
Jerzy Szewczyk +2 more
openaire +1 more source